• Product
      • Active Ingredient
      • Dosage Form
      • Dosage Strength
      • Provider
      • Indication
      • Stalevo®
      • Entacapone (Compound)
      • Tablet
      • 150/200/37.5 mg
      • Novarits
      • Treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase(DDC) inhibitor treatment.